CN101616928B - 新型大分子转导域及其识别方法和用途 - Google Patents

新型大分子转导域及其识别方法和用途 Download PDF

Info

Publication number
CN101616928B
CN101616928B CN200880003468.9A CN200880003468A CN101616928B CN 101616928 B CN101616928 B CN 101616928B CN 200880003468 A CN200880003468 A CN 200880003468A CN 101616928 B CN101616928 B CN 101616928B
Authority
CN
China
Prior art keywords
leu
ala
mtd
val
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880003468.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101616928A (zh
Inventor
赵大雄
高在仙
金珍淑
朴警湄
宋珍京
林贞姬
杜翠娥
杜兰凤
杨铭三
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Foundation of Chonnam National University
Original Assignee
Industry Foundation of Chonnam National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Foundation of Chonnam National University filed Critical Industry Foundation of Chonnam National University
Publication of CN101616928A publication Critical patent/CN101616928A/zh
Application granted granted Critical
Publication of CN101616928B publication Critical patent/CN101616928B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200880003468.9A 2007-01-29 2008-01-29 新型大分子转导域及其识别方法和用途 Active CN101616928B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88706007P 2007-01-29 2007-01-29
US60/887,060 2007-01-29
PCT/KR2008/000525 WO2008093982A1 (en) 2007-01-29 2008-01-29 Novel macromolecule transduction domains and methods for identification and uses thereof

Publications (2)

Publication Number Publication Date
CN101616928A CN101616928A (zh) 2009-12-30
CN101616928B true CN101616928B (zh) 2015-04-15

Family

ID=39674245

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880003468.9A Active CN101616928B (zh) 2007-01-29 2008-01-29 新型大分子转导域及其识别方法和用途

Country Status (8)

Country Link
US (2) US8629097B2 (enExample)
EP (2) EP2129682A4 (enExample)
JP (3) JP5518488B2 (enExample)
KR (18) KR20090103957A (enExample)
CN (1) CN101616928B (enExample)
AU (1) AU2008211854C1 (enExample)
CA (1) CA2676797C (enExample)
WO (1) WO2008093982A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8158415B2 (en) 2007-02-27 2012-04-17 Procell Therapeutics Inc. Combined use of cell permeable Nanog and Oct4 for increasing self-renewal and suppressing differentiation of stem cells
EP2185707B1 (en) * 2007-09-04 2013-07-03 Procell Therapeutics Inc. Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same
KR100887266B1 (ko) * 2007-09-04 2009-03-06 주식회사 프로셀제약 세포투과성 ｐ１８ 재조합 단백질, 이를 코딩하는폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암조성물
WO2009061130A2 (en) * 2007-11-06 2009-05-14 Procell Therapeutics Inc. Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same
WO2009145489A2 (ko) 2008-04-04 2009-12-03 주식회사 프로셀제약 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
US20120095188A1 (en) 2009-03-12 2012-04-19 Procell Therapeutics Inc. Establishment of induced pluripotent stem cell using cell-permeable reprogramming transcription factor for customized stem cell therapy
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
TW201302800A (zh) * 2011-06-10 2013-01-16 腫瘤療法 科學股份有限公司 Ｓｅｍａ５ｂ胜肽及含其之疫苗
KR102067760B1 (ko) 2011-08-16 2020-01-17 삼성전자주식회사 세포 내 전달용 단백질 복합체 및 그의 용도
US9259481B2 (en) 2011-11-23 2016-02-16 Procell Therapeutics Inc. Development of novel macromolecule transduction domain with improved cell permeability and method for using same
KR101258279B1 (ko) * 2011-11-23 2013-04-25 주식회사 프로셀제약 세포 투과능을 개선한 개량형 신규 거대 분자 전달 도메인 개발 및 이의 이용방법
KR101393397B1 (ko) * 2011-11-23 2014-05-14 주식회사 프로셀제약 세포내 분자 전송 펩티드를 이용한 피부 생리 활성 분자의 경피 전달시스템
CN104507961B (zh) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
WO2013169077A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 악액질 예방 또는 치료용 조성물
CA2877384C (en) 2012-07-02 2023-05-09 Iprogen Biotech Inc. Intracellular protein delivery
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
WO2014046481A1 (ko) * 2012-09-19 2014-03-27 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
CN104981478B (zh) * 2012-09-19 2019-02-22 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
JP6059405B2 (ja) 2013-06-07 2017-01-11 ジェムバックス アンド カエル カンパニー，リミティド 癌の免疫学的治療に有用な生物学的マーカー
WO2014204281A1 (ko) 2013-06-21 2014-12-24 주식회사 카엘젬백스 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
GB201315321D0 (en) * 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer
ES2773296T3 (es) 2013-10-23 2020-07-10 Gemvax & Kael Co Ltd Composición para tratar y prevenir la hiperplasia prostática benigna
KR102359396B1 (ko) 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
CA2940057C (en) 2014-02-20 2017-05-30 Cura Health Inc. Transdermal composition for treating pain
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
CN106659149B (zh) 2014-04-30 2020-05-19 珍白斯凯尔有限公司 用于器官、组织或细胞移植的组合物、试剂盒和移植方法
KR101882461B1 (ko) * 2014-05-29 2018-07-27 주식회사 프로셀테라퓨틱스 신규한 세포투과성 펩타이드 및 이와 보툴리눔 독소 결합체 및 이들의 용도
CN107074910B (zh) * 2014-08-17 2022-02-18 塞里维瑞疗法公司 高级大分子转导域序列、编码其的多核苷酸及其用途
US20160060310A1 (en) 2014-08-27 2016-03-03 Daewoong Jo Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Hepatocellular Carcinoma Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Hepatocellular Carcinoma Compositions Comprising the Same
CN104548073B (zh) * 2014-12-12 2017-08-11 浙江大学 Prx I重组蛋白在制备抗细菌性败血症药物中的应用
CN107108756A (zh) * 2014-12-22 2017-08-29 豪夫迈·罗氏有限公司 细胞穿透性肽
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
JP6751097B2 (ja) 2015-02-27 2020-09-02 ジェムバックス アンド カエル カンパニー，リミティド 聴力損傷予防用ペプチド及びそれを含む組成物
KR102911237B1 (ko) 2015-05-26 2026-01-13 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
US20170029798A1 (en) 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
EP3334755B1 (en) * 2015-08-10 2020-04-08 Cellivery Therapeutics, Inc. Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof
WO2017026779A1 (en) * 2015-08-10 2017-02-16 Cellivery Therapeutics, Inc. Improved cell-permeable cre (icp-cre) recombinant protein and use thereof
WO2017030323A1 (en) 2015-08-18 2017-02-23 Cellivery Therapeutics, Inc. Cell-permeable (cp)-δsocs3 recombinant protein and uses thereof
GB201521101D0 (en) 2015-11-30 2016-01-13 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction buffer
KR101800407B1 (ko) * 2016-04-04 2017-11-22 건국대학교 산학협력단 비단뱀으로부터 분리한 신규한 항균 펩타이드 및 이의 발굴 방법
EP4272829A3 (en) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
CN118909050A (zh) * 2016-10-12 2024-11-08 费尔丹生物公司 用于将多肽负荷递送至靶真核细胞的合理设计的合成肽穿梭剂，其用途、方法和试剂盒
US11517616B2 (en) 2016-10-23 2022-12-06 Denka Company Limited Composite polypeptide monomer, aggregate of said composite polypeptide monomer having cell penetration function, and norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration and having said aggregate as effective component thereof
CN106831957B (zh) * 2017-04-17 2019-12-03 扬州大学 一种源于鸡传染性贫血病毒VP1-aa 1-19多肽作为高效细胞穿膜肽的应用
CN106995487B (zh) * 2017-04-17 2019-12-03 扬州大学 源于鸡传染性贫血病毒VP1-aa 23-43多肽作为高效细胞穿膜肽的应用
WO2019108047A2 (ko) 2017-12-01 2019-06-06 주식회사 굳티셀 탈모의 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1065929A (zh) * 1991-04-11 1992-11-04 住友电气工业株式会社 测量涂层状态的方法和设备
WO1999049879A1 (en) * 1998-03-31 1999-10-07 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
WO2003097671A1 (en) * 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
WO2002064057A2 (en) * 2001-02-15 2002-08-22 Baylor College Of Medicine Use of cell penetrating peptides to generate antitumor immunity
US6835810B2 (en) * 2002-05-13 2004-12-28 Geneshuttle Biopharma, Inc. Fusion protein for use as vector
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20040043463A1 (en) * 2002-09-03 2004-03-04 Pingfan Rao Peptide-tagged proteins and compositions for regulating features of the skin or hair; methods of making, and methods of using thereof
US20070154437A1 (en) 2002-09-03 2007-07-05 Pingfan Rao Peptide-tagged proteins and methods of making and using thereof
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1065929A (zh) * 1991-04-11 1992-11-04 住友电气工业株式会社 测量涂层状态的方法和设备
WO1999049879A1 (en) * 1998-03-31 1999-10-07 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
WO2003097671A1 (en) * 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof

Also Published As

Publication number Publication date
KR20200029404A (ko) 2020-03-18
US9040477B2 (en) 2015-05-26
AU2008211854B2 (en) 2012-08-16
KR20200028361A (ko) 2020-03-16
KR20200028362A (ko) 2020-03-16
KR102217320B1 (ko) 2021-02-18
KR20200028355A (ko) 2020-03-16
KR20200028363A (ko) 2020-03-16
KR102217325B1 (ko) 2021-02-18
KR102217317B1 (ko) 2021-02-18
WO2008093982A1 (en) 2008-08-07
KR102217310B1 (ko) 2021-02-18
CA2676797C (en) 2014-04-22
KR20200028357A (ko) 2020-03-16
AU2008211854C1 (en) 2014-01-23
KR102217331B1 (ko) 2021-02-18
US20140186379A1 (en) 2014-07-03
KR20200028356A (ko) 2020-03-16
EP2837636A3 (en) 2015-07-15
EP2129682A1 (en) 2009-12-09
KR102217281B1 (ko) 2021-02-18
KR102217299B1 (ko) 2021-02-18
KR20200027934A (ko) 2020-03-13
CA2676797A1 (en) 2008-08-07
KR102217304B1 (ko) 2021-02-18
KR20200028353A (ko) 2020-03-16
KR20200028354A (ko) 2020-03-16
KR20200027935A (ko) 2020-03-13
KR102217295B1 (ko) 2021-02-18
KR102217269B1 (ko) 2021-02-18
EP2837636A2 (en) 2015-02-18
KR102217277B1 (ko) 2021-02-18
JP5518488B2 (ja) 2014-06-11
JP2015146820A (ja) 2015-08-20
KR20200028364A (ko) 2020-03-16
KR20200028359A (ko) 2020-03-16
KR20090103957A (ko) 2009-10-01
KR102217321B1 (ko) 2021-02-18
KR102217274B1 (ko) 2021-02-18
CN101616928A (zh) 2009-12-30
KR102254723B1 (ko) 2021-05-24
AU2008211854A1 (en) 2008-08-07
KR20200029405A (ko) 2020-03-18
EP2129682A4 (en) 2011-07-20
JP6140759B2 (ja) 2017-05-31
JP2014057586A (ja) 2014-04-03
KR102217308B1 (ko) 2021-02-18
KR102217324B1 (ko) 2021-02-18
KR102217313B1 (ko) 2021-02-18
KR20200028360A (ko) 2020-03-16
US20100197598A1 (en) 2010-08-05
EP2837636B1 (en) 2018-04-11
KR20160068704A (ko) 2016-06-15
US8629097B2 (en) 2014-01-14
KR20200028358A (ko) 2020-03-16
JP2010516758A (ja) 2010-05-20

Similar Documents

Publication Publication Date Title
CN101616928B (zh) 新型大分子转导域及其识别方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant